EGFR and lung adenocarcinoma: Advances in the treatment of patients with lung adenocarcinoma were made with the introduction of molecularly targeted approaches, such as the use of tyrosine-kinase inhibitors for patients with tumors containing activating, sensitizing EGFR mutations [4] and Crizotinib for ALK rearrangements [5].